Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 83, Issue 6, 2012, Pages 601-606

  Poletti, Michele ^a,b   Frosini, Daniela ^a   Pagni, Cristina ^a   Baldacci, Filippo ^a,b   Nicoletti, Valentina ^a   Tognoni, Gloria ^a   Lucetti, Claudio ^b   Del Dotto, Paolo ^b   Ceravolo, Roberto ^a   Bonuccelli, Ubaldo ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b USL of Viareggio   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BRADYKINESIA; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; EPISODIC MEMORY; EXECUTIVE FUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MOTOR ACTIVITY; MOTOR DYSFUNCTION; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; TASK PERFORMANCE; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; VERBAL MEMORY;

AGED; EXECUTIVE FUNCTION; FEMALE; HUMANS; HYPOKINESIA; ITALY; MALE; MEMORY, EPISODIC; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PREVALENCE; PSYCHOMOTOR PERFORMANCE; SEVERITY OF ILLNESS INDEX; TREMOR;

EID: 84860917470     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2011-301874     Document Type: Article

References (40)

1. Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 2005;62:1160-3. (Pubitemid 41043744)
2. Poletti M, Emre M, Bonuccelli U. Mild cognitive impairment and cognitive reserve in Parkinson's disease. Parkinsonism Relat Disord 2011;17:579-86.
3. Litvan I, Aarsland D, Adler CH, et al. MDS task force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord 2011;26:1814-24.
4. Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson's disease: a multicenter pooled analysis. Neurology 2010;75:1062-9.
5. Janvin CC, Larsen JP, Aarsland D, et al. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006;21:1343-9. (Pubitemid 44613283)
6. Williams-Gray CH, Foltynie T, Brayne CE, et al. Evolution of cognition in an incident Parkinson's disease cohort. Brain 2007;130:1787-98. (Pubitemid 47343805)
7. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndrome of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009;132:2958-69.
8. Kulisevsky J, Garcia-Sanchez C, Berthier ML, et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov Disord 2000;15:613-26. (Pubitemid 30479613)
9. Fera F, Nicoletti G, Cerasa A, et al. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease. Brain Res Bull 2007;74:75-83. (Pubitemid 47187915)
10. Foltynie T, Brayne CE, Robbins TW, et al. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004;127:550-60. (Pubitemid 38295472)
11. Dujardin K, Defebvre L, Duhamel A, et al. Cognitive and SPECT characteristics predict progression of Parkinson's disease in newly diagnosed patients. J Neurol 2004;251:1383-92.
12. Muslimovic D, Post B, Speelman JD, et al. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005;65:1239-45. (Pubitemid 41508217)
13. Aarsland D, Bronnick K, Larsen JP, et al; Norwegian ParkWest Study Group. Cognitive impairment in incident, untreated Parkinson's disease: the Norwegian ParkWest Study. Neurology 2009;72:1121-6.
14. Elgh E, Domeloff M, Linder J, et al. Cognitive function in early Parkinson's disease: a population-based study. Eur J Neurol 2009;16:1278-84.
15. Martin WR, Wieler M, Gee M, et al. Temporal lobe changes in early, untreated Parkinson's disease. Mov Disord 2009;24:1949-54.
16. Jellinger KE. Neuropathology in Parkinson's disease with mild cognitive impairment. Acta Neuropathol 2010;120:829-30.
17. Troster AI. A précis of recent advances in the neuropsychology of mild cognitive impairment(s) in Parkinson's disease and a proposal of preliminary research criteria. J Int Neuropsychol Soc. Published Online First: 8 April 2011. doi:10.1017/S1355617711000257
18. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a baseline analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990;40:1529-34. (Pubitemid 20351344)
19. Fahn S, Elton RL. Members of the UPDRS development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, et al, eds. Recent Developments in Parkinson's Disease. Vol. 2. Macmillan Health Care Information: Florham Park, NJ, 1987:153-64.
20. Burn DJ, Rowan EN, Allan LM, et al. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006;77:585-9. (Pubitemid 43844579)
21. Sollinger AB, Goldtsein FC, Lah JJ, et al. Mild cognitive impairment in Parkinson's disease: subtypes and motor characteristics. Parkinsonism Relat Disord 2010;16:177-80.
22. Taylor JP, Rowan EN, Lett D, et al. Poor attentional function predicts cognitive decline in patients with non-demented Parkinson's disease independent of motor phenotype. J Neurol Neurosurg Psychiatry 2008;79:1318-23.
23. Uc EY, McDermott MP, Marder KS, et al. Incidence of risk factors for cognitive impairment in a early clinical Parkinson disease clinical trial cohort. Neurology 2009;73:1469-77.
24. Domellof ME, Elgh E, Forsgren L. The relation between cognition and motor dysfunction in drug-naïve newly diagnosed patients with Parkinson's disease. Mov Disord 2011;26:2183-9.
25. Hugues AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;155:181-4.
26. Sheik JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. In: Clinical Gerontology. A Guide Assess Intervention. The Haworth Press: NY, 1986:165-73. (Pubitemid 17221439)
27. American Psychiatric Association. Diagnostic and Statistic Manual of Mental Disorders IV Edition Text Revision. Washington DC: APA Press, 2000.
28. Folstein MF, Folstein SE, McHugh PR. Mini Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
29. Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008;23:183-9. (Pubitemid 351311545)
30. Ishihara-Paul L, Wainwright NW, Khaw KT, et al. Prospective association between emotional health and clinical evidence of Parkinson's disease. Eur J Neurol 2008;15:1148-54.
31. Vingerhoerts FJ, Schulzer M, Caine DB, et al. Which clinical sign of Parkinson's disease reflects the nigrostriatal lesion? Ann Neurol 1997;41:58-64. (Pubitemid 27057093)
32. Cools R, Barker RA, Sahakian BJ, et al. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 2001;11:1136-43. (Pubitemid 33108240)
33. Kehagia A, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010;9:1200-13.
34. Lyoo CH, Jeong Y, Ryu YH, et al. Cerebral glucose metabolism of Parkinson's disease patients with mild cognitive impairment. Eur J Neurol 2010;64:65-73.
35. Hosokai Y, Nishio Y, Hirayama K, et al. Distinct patterns of cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment. Mov Disord 2009;23:854-62.
36. Nobili F, Arnaldi D, Campus C, et al. Brain perfusion correlates of cognitive and nigrostriatal functions in de novo Parkinson's disease. Eur J Nucl Med Mol Imaging 2011;38:2209-18.
37. Pappatà S, Santangelo G, Aarsland D, et al. Mild cognitive impairment in drug-naïve patients with PD is associated with cerebral hypometabolism. Neurology 2011;77:1357-62.
38. Mo SJ, Linder J, Forsgren L, et al. Pre and postsynaptic dopamine SPECT in the early phase of idiopathic parkinsonism: a population-based study. Eur J Nucl Med Mol Imaging 2010;37:2154-64.
39. Selikhova M, Williams DR, Kempster PA, et al. A clinico-pathological study of subtypes in Parkinson's disease. Brain 2009;132:2947-57.
40. Jellinger K. Heterogeneous mechanisms of mild cognitive impairment in Parkinson's disease. J Neural Transm 2012;119:381-2.